According to the Zhitong Finance App, Weitai Medical-B (02235.HK) announced that the Group's revenue for the six months ended June 30, 2026 (reporting period) will be no less than RMB 400 million, compared with RMB 246 million for the six months ended June 30, 2025, an increase of no less than 63% over the previous year. It is estimated that the Group's net profit attributable to owners of the parent company during the reporting period will not be less than RMB 36 million, which will turn a loss into a profit compared to RMB 2 million for the six months ended June 30, 2025.

According to the Zhitong Finance App, Weitai Medical-B (02235.HK) announced that the Group's revenue for the six months ended June 30, 2026 (reporting period) will be no less than RMB 400 million, compared with RMB 246 million for the six months ended June 30, 2025, an increase of no less than 63% over the previous year. It is estimated that the Group's net profit attributable to owners of the parent company during the reporting period will not be less than RMB 36 million, which will turn a loss into a profit compared to RMB 2 million for the six months ended June 30, 2025.